Δημοσιεύσεις

Μαυραγάνη Κλειώ

h-index: 40, citations 5151top-5 δημοσιεύσεις τελευταίας 5-ετίας:

1. Flessa CM, Zampeli E, Evangelopoulos ME, Natsis V, Bodewes ILA, Huijser E, Versnel MA, Moutsopoulos HM, Mavragani CP. Genetic Variants of the ΒΑFF Gene and Risk of Fatigue Among Patients With Primary Sjögren’s Syndrome. FrontImmunol. 2022 Mar 15;13:836824.

2. Cinoku II, Verrou KM, Piperi E, Voulgarelis M, Moutsopoulos HM, Mavragani CP. Interferon (IFN)-stimulated gene 15: A novel biomarker for lymphoma development in Sjögren’s syndrome. J Autoimmun. 2021 Sep;123:102704.

3. Nezos A, Skarlis C, Psarrou A, Markakis K, Garantziotis P, Papanikolaou A, Gravani F, Voulgarelis M, Tzioufas AG, Koutsilieris M, Moutsopoulos HM, Kotsifaki E, Mavragani CP. Lipoprotein-Associated Phospholipase A2: A Novel Contributor in Sjögren’s Syndrome-Related Lymphoma? Front Immunol. 2021 Jun 18;12:683623.

4. Theodorou E, Nezos A, Antypa E, Ioakeimidis D, Koutsilieris M, Tektonidou M, Moutsopoulos HM, Mavragani CP. B-cell activating factor and related genetic variants in lupus related atherosclerosis. J Autoimmun. 2018 Aug;92:87-92.

5. Mavragani CP, Nezos A, Sagalovskiy I, Seshan S, Kirou KA, Crow MK. Defective regulation of L1 endogenous retroelements in primary Sjogren’s syndrome and systemic lupus erythematosus: Role of methylating enzymes. J Autoimmun. 2018Mar;88:75-82.

 

Γιαννούλη Σταυρούλα

h-index 25, citations 1697

1. Poulaki A, Katsila T, Stergiou IE, Giannouli S*, Gόmez-Tamayo JC, Piperaki ET, Kambas K, Dimitrakopoulou A, Patrinos GP, Tzioufas AG, Voulgarelis M. Bioenergetic Profiling of the Differentiating Human MDS Myeloid Lineage with Low and High Bone Marrow Blast Counts. Cancers (Basel). 2020 Nov 26;12(12):3520.

2. Stergiou IE, Kambas K, Poulaki A, Giannouli S*, Katsila T, Dimitrakopoulou A, Vidali V, Mouchtouris V, Kloukina I, Xingi E, Pagakis SN, Probert L, Patrinos GP, Ritis K, Tzioufas AG, Voulgarelis M. Exploiting the Role of Hypoxia- Inducible Factor 1 and Pseudohypoxia in the Myelodysplastic Syndrome Pathophysiology. Int J Mol Sci. 2021 Apr 15;22(8):4099.

3. Poulaki A, Giannouli S. Metabolic Swifts Govern Normal and Malignant B Cell Lymphopoiesis. Int J Mol Sci. 2021 Jul 31;22(15):8269.

4.Poulaki, A.; Giannouli, S. Mitochondrial Lipids: From Membrane Organization to Apoptotic Facilitation. Int. J. Mol. Sci. 2022, 23, 3738.

5. Grigoriou M, Banos A, Filia A, Pavlidis P, Giannouli S, Karali V, Nikolopoulos D, Pieta A, Bertsias G, Verginis P, Mitroulis I, Boumpas DT. Transcriptome reprogramming and myeloid skewing in haematopoietic stem and progenitor cells in systemic lupus erythematosus. Ann Rheum Dis. 2020 Feb;79(2):242-253.

 

Αλισσάφη Θέμις

h-index: 16, citations 1100top-5

δημοσιεύσεις τελευταίας 5-ετίας:

1. Grigoriou Μ., Banos Α., Hatzioannou Α., Kloetgen Α., Kouzis P., Aggouraki D., Zakopoulou R., Bamias G., Kassi E., Mavroudis D., Bamias A., Boumpas D.T., Tsirigos A., Gogas H., Verginis P*., Alissafi T*. Regulatory T cell transcriptomic reprogramming denominates adverse events induced by checkpoint inhibitors in solid tumors., Cancer Immunology Research, 2021

2. Alissafi T*., Kalafati L., Lazari M., Alexaki I., Chavakis T., Verginis P*. (*correspondence). Mitochondrial Oxidative Damage Underlies Regulatory T Cell Defects in Autoimmunity, Cell Metabolism, 2020.

3. Alissafi T, Hatzioannou A, Legaki AI, Varveri A, Verginis P. Balancing cancer immunotherapy and immune-related adverse events: The emerging role of regulatory T cells. J Autoimmun. 2019 Aug.

4. Alissafi T, Hatzioannou A, Mintzas K, Barouni RM, Banos A, Sormendi S, Polyzos A, Xilouri M, Wielockx B, Gogas H and Verginis P. Autophagy orchestrates the regulatory program of tumor-associated myeloid-derived suppressor cells. J Clin Invest. 2018 Jun 19. pii: 120888.

5. Alissafi T, Banos A, Boon L, Sparwasser T, Ghigo A, Wing K, Vassilopoulos D, Boumpas D, Chavakis T, Cadwell K, Verginis P. Tregs restrain dendritic cell autophagy to ameliorate autoimmunity. J Clin Invest. 2017 Jun

 

Ευαγγελοπούλου Μαρία Ελευθερία

h-index: 21 , citations: 1318 top-5 δημοσιεύσεις τελευταίας 5-ετίας:

1. Evangelopoulos ME, Nasiri-Ansari N, Kassi E, Papadopoulou A, Evangelopoulos, DS, Moutsatsou P. Methylprednisolone stimulated gene expression (GILZ, MCL-1) and basal cortisol levels in multiple sclerosis patients in relapse are associated with clinical response. Sci Rep. 2021 Sep 30;11(1):19462.

2. Mavragani CP, Karathanasis D, Velonakis G, Nezos A, Kilidireas C, Evangelopoulos ME. Scleroderma specific autoantibodies and MS-like manifestations: A novel association? Autoimmun Rev. 2021 Aug;20(8):102871.

3. Sereti E, Stamatelopoulos KS, Zakopoulos NA, Evangelopoulou A, Mavragani CP, Evangelopoulos ME. Hypertension: An immune related disorder? Clin Immunol. 2020 Mar;212:108247.

4. Zoehner G, Miclea A, Salmen A, Kamber N, Diem L, Friedli C, Bagnoud M, Ahmadi F, Briner M, Sédille-Mostafaie N, Kilidireas C, Stefanis L, Chan A, Hoepner R, Evangelopoulos ME. Reduced serum immunoglobulin G concentrations in multiple sclerosis: prevalence and association with disease-modifying therapy and disease course. Ther Adv Neurol Disord. 2019 Sep 27;12:1756286419878340.

5. Evangelopoulos ME, Miclea A, Schrewe L, Briner M, Salmen A, Engelhardt B, Huwiler A, Chan A, Hoepner R. Frequency and clinical characteristics of Multiple Sclerosis rebounds after withdrawal of Fingolimod. CNS Neurosci Ther. 2018Oct;24(10):984-986.

 

Τσιριγώτης Παναγιώτης

h-index: 29, citations: 2450 top-5 δημοσιεύσεις τελευταίας 5-ετίας:

1. Tsirigotis P, Gkirkas K, Kitsiou V, Chondropoulos S, Athanassiades T, Thomopoulos T, Tsirogianni A, Stamouli M, Karagiannidi A, Siafakas N, Pappa V, Nagler A. Repetitively Administered Low-Dose Donor Lymphocyte Infusion forPrevention of Relapse after Allogeneic Stem Cell Transplantation in Patients with High-Risk Acute Leukemia. Cancers (Basel). 2021 May 30;13(11):2699. doi: 10.3390/cancers13112699. PMID: 34070786; PMCID: PMC8198731.

2. Gkirkas K, Stamouli M, Karagiannidou A, Chondropoulos S, Tsirigotis P. Extramedullary leukemia relapse after allogeneic stem cell transplantation: a novel mechanism of immune escape? Immunotherapy. 2020 Jun;12(9):635-640. doi: 10.2217/imt-2019-0215. Epub 2020 May 21. PMID: 32436474.

3. Tsirogianni M, Grigoriou E, Kapsimalli V, Dagla K, Stamouli M, Gkirkas K, Konsta E, Karagiannidou A, Gkodopoulos K, Stavroulaki G, Pappa V, Angelopoulou M, Lowdell M, Tsirigotis P. Natural killer cell cytotoxicity is a predictor ofoutcome for patients with high risk myelodysplastic syndrome and oligoblastic acute myeloid leukemia treated with azacytidine. Leuk Lymphoma. 2019 Oct;60(10):2457-2463. doi: 10.1080/10428194.2019.1581935. Epub 2019 Apr 5. PMID: 30947589.

4. Tsirigotis P, Vassilakopoulos T, Batsis I, Bousiou Z, Gkirkas K, Sakellari I, Kaloyannidis P, Roussou P, Pangalis GA, Moschogiannis M, Vassilopoulos G, Repousis P, Megalakaki A, Michalis E, Kalpadakis C, Papadaki HA, Kotsianidis I, Hatzimichael E, Spyridonidis A, Anargyrou K, Poulakidas E, Giannoullia P, Apostolidis I, Stamouli M, Konstantopoulos K, Pappa V, Panayiotidis P, Harhalakis N, Anagnostopoulos A, Angelopoulou M. Positive impact of brentuximab vedotin on overall survival of patients with classical Hodgkin lymphoma who relapse or progress after autologous stem cell transplantation: A nationwide analysis. Hematol Oncol. 2018 Oct;36(4):645-650. doi: 10.1002/hon.2521. Epub2018 Jun 8. PMID: 29882363.

5. Angelopoulou MK, Vassilakopoulos TP, Batsis I, Sakellari I, Gkirkas K, Pappa V, Giannoulia P, Apostolidis I, Apostolopoulos C, Roussou P, Panayiotidis P, Dimou M, Kyrtsonis MC, Palassopoulou M, Vassilopoulos G, Moschogiannis M, Kalpadakis C, Margaritis D, Spyridonidis A, Michalis E, Anargyrou K, Repousis P, Hatzimichael E, Bousiou Z, Poulakidas E, Grentzelias D, Harhalakis N, Pangalis GA, Anagnostopoulos A, Tsirigotis P. Brentuximab vedotin in relapsed/refractoryHodgkin lymphoma. The Hellenic experience. Hematol Oncol. 2018 Feb;36(1):174-181.